Globus Medical, Inc. Q3 2025 Earnings Recap

GMED Q3 2025 November 8, 2025

Get alerts when GMED reports next quarter

Globus Medical reported a robust Q3 2025, with sales increasing 22.9% to $769 million and non-GAAP EPS jumping 42.6% to $1.18, driven by strong growth in both the U.S. and international spine markets.

Earnings Per Share Beat

$1.18 vs $0.78 est.

+51.1% surprise

Revenue Beat

769048000 vs 734694046 est.

+4.7% surprise

Market Reaction

1-Day +0.0%

5-Day +0.12%

30-Day +4.6%

See GMED alongside your other holdings

Add to your portfolio — free

Key Takeaways

Base business revenue rose to $669.8 million, with an adjusted EBITDA margin improvement of 435 basis points to 35.3%.
Free cash flow reached a record $213.9 million, underlining operational efficiency and strong cash generation.
The U.S. Spine segment grew by 9.6%, maintaining positive momentum with 32 consecutive weeks of growth.
The recently acquired Nevro business contributed $99.3 million in revenue, enhancing overall business expansion.
Strategic share repurchases totaled $40 million during the quarter, reflecting confidence in long-term growth and shareholder value.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GMED on AllInvestView.

Next Q1 2026